Raptor Set To Fly As Commercial Company With Procysbi Approval
This article was originally published in The Pink Sheet Daily
Procysbi was approved by FDA April 30 for the ultra-rare disease nephropathic cystinosis and will be priced in line with other orphan drugs at an average annual cost per patient of $250,000.
You may also be interested in...
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.